Decision: Favourable
Study Title:
A Phase 3, Two-Stage, Randomized, Multicenter, Open Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
NREC Code:
22-NREC-CT-164
Decision:
Favourable
Meeting Date:
09/11/2022
Study Type:
CT Application
Principal Investigator:
Dr Patrick Hayden
PI Institution:
St James's Hospital
Sponsor:
Celgene Corporation